PARLIAMENTARY WRITTEN QUESTION
(30 May 2025)

To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on ensuring that the Single Technology Appraisal process takes into account the health-related quality-of-life impacts on carers for (a) all and (b) rare disease therapies.

Asked by:
John Milne (Liberal Democrat)

The National Institute for Health and Care Excellence’s (NICE) technology appraisal process allows its independent committees to take all health-related costs and benefits, including health-related quality-of-life for carers, and impacts on personal social services, into account. The NICE’s methods are set out in its published health technology evaluations manual, which is available at the following link:

https://www.nice.org.uk/process/pmg36

Evaluations should consider all health effects for patients, and, when relevant, carers. When presenting health effects for carers, evidence should show when a condition is associated with a substantial effect on a carer’s health-related quality of life, and how the technology affects carers. This applies for all therapies, including therapies for rare diseases. NICE appraisals specifically consider health-related quality of life, for both patients and carers, rather than quality of life as a whole.

Answered by:
()